A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ARGENX SE
ARGX
$41.7B
Mkt Cap
$918.22
-0.69%
ARGENX SE (ARGX) has a 5-year average return on invested capital (ROIC) of 6.2%. This is below average and may indicate limited pricing power.
ARGENX SE (ARGX) has a market capitalization of $41.7B. It is classified as a large-cap stock.
ARGENX SE (ARGX) does not currently pay a regular dividend.
ARGENX SE (ARGX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ARGENX SE (ARGX) generated $-347 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ARGENX SE (ARGX) reported earnings per share (EPS) of $-11.65 in its most recent fiscal year.
The Ledger Terminal provides 6 years of financial data for ARGENX SE (ARGX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Not applicable. ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable. ITEM 3. KEY INFORMATION B. CAPITALIZATION AND INDEBTEDNESS Not applicable. C. REASONS FOR THE OFFER AND USE OF PROCEEDS Not applicable. D. RISK FACTORS
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 36M | 15M |
| Net Income | -529M | -529M | -163M | -67M | -28M | -21M |
| EPS | $-11.65 | $-11.65 | $-4.22 | $-1.99 | $-1.14 | $-1.14 |
| Free Cash Flow | -347M | -347M | 133M | -54M | -37M | 9.8M |
| ROIC | - | - | - | - | 7.6% | 4.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | - | - | 0.08 | 0.67 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -526M | -526M | 13M | 7.7M | 4.8M | 2.4M |
| Operating Margin | 0.0% | - | - | - | 13.3% | 16.6% |
| ROE | 0.0% | - | - | - | -13.8% | -42.5% |
| Shares Outstanding | 45M | 45M | 39M | 33M | 25M | 19M |
| Metric | 2015 | 2016 | TTM | ||||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | 15M | 36M | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 21M | 32M | 52M | 84M | 198M | 325M | 325M |
| SG&A | 4.9M | 7.0M | 12M | 27M | 65M | 149M | 149M |
| EBIT | 3.1M | 2.4M | 4.8M | 7.7M | 13M | -526M | -526M |
| Op. Margin | N/A | 16.6% | 13.3% | N/A | N/A | N/A | 0.0% |
| Net Income | -15M | -21M | -28M | -67M | -163M | -529M | -529M |
| Net Margin | N/A | -145.3% | -77.1% | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 6.6% | 4.8% | 7.6% | N/A | N/A | N/A | N/A |
| ROE | -41.1% | -42.5% | -13.8% | N/A | N/A | N/A | 0.0% |
| ROA | -33.3% | -20.2% | -11.8% | N/A | N/A | N/A | 0.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -14M | 11M | -37M | -54M | 135M | -346M | -346M |
| Free Cash Flow | -14M | 9.8M | -37M | -54M | 133M | -347M | -347M |
| Owner Earnings | -14M | 10M | -37M | -54M | 132M | -350M | -350M |
| CapEx | 274K | 840K | 345K | 622K | 1.6M | 949K | 949K |
| Maint. CapEx | 191K | 323K | 425K | 474K | 2.1M | 3.2M | 3.2M |
| Growth CapEx | 83K | 517K | 0 | 148K | 0 | 0 | 0 |
| D&A | 191K | 323K | 425K | 474K | 2.1M | 3.2M | 3.2M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 1.2% | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Cash & Equiv. | 36M | 90M | 191M | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.23 | 0.67 | 0.08 | N/A | N/A | N/A | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | 103.2 | -1506.6 | -1506.6 |
| Equity | 37M | 63M | 345M | N/A | N/A | N/A | 0 |
| Total Assets | 46M | 106M | 371M | N/A | N/A | N/A | 0 |
| Total Liabilities | 8.7M | 42M | 26M | N/A | N/A | N/A | N/A |
| Intangibles | 7K | 17K | 13K | N/A | N/A | N/A | N/A |
| Retained Earnings | -51M | -72M | -101M | N/A | N/A | N/A | N/A |
| Working Capital | 35M | 69M | 366M | N/A | N/A | N/A | N/A |
| Current Assets | 44M | 102M | 367M | N/A | N/A | N/A | N/A |
| Current Liabilities | 8.7M | 32M | 597K | N/A | N/A | N/A | N/A |
| Per Share Data | |||||||
| EPS | -0.97 | -1.14 | -1.14 | -1.99 | -4.22 | -11.65 | -11.65 |
| Owner EPS | -0.44 | 0.55 | -1.50 | -1.62 | 3.43 | -7.70 | -7.70 |
| Book Value | 1.16 | 3.38 | 14.01 | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | -0.43 | 0.57 | -1.48 | -1.61 | 3.49 | -7.63 | -11.58 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 32.2M | 18.7M | 24.6M | 33.5M | 38.6M | 45.4M | 45.4M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -78.8 |
| P/FCF | N/A | N/A | N/A | N/A | 46.7 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.5 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 17.2 | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -2.4% | -1.7% | 2.1% | -2.5% | -0.8% |
| Market Cap | N/A | N/A | 1.5B | 3.2B | 6.2B | 13.7B | 41.7B |
| Avg. Price | N/A | N/A | 25.38 | 85.48 | 128.36 | 209.00 | 918.22 |
| Year-End Price | N/A | N/A | 62.54 | 97.03 | 160.80 | 301.01 | 918.22 |
ARGENX SE passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 6.2%. At current prices, the estimated annualized return to fair value is +7.1%.